by cognosadminteam | Sep 20, 2023 | News
Nocturne Acquisition Engages Chardan As Capital Markets Advisor for Cognos Acquisition 20 SEPTEMBER, 2023 Chardan Engaged to Facilitate Nocturne Acquisition Corporation’s Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing....
by cognosadminteam | Aug 17, 2023 | News
Nocturne Acquisition Files S-4 In Advance of Cognos' Listing On The NASDAQ 16 AUGUST, 2023 Nocturne Acquisition Corporation Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Cognos. WILLMINGTON, DE. It...
by cognosadminteam | Jan 3, 2023 | News
3 JANUARY, 2023 Cognos Therapeutics announced it has finalized a definitive agreement with Nocturne Acquisition Corporation to take the company public on the Nasdaq Stock Exchange. LOS ANGELES, CA. It was announced today on several financial news outlets that Cognos...
by cognosadminteam | Jan 7, 2022 | News
7 JANUARY, 2022 Report Stresses The Need To Develop Better Methods of Delivery for Therapeutics for Brain-Based Diseases. LOS ANGELES, CA. In an article published on LabRoots. com, by Dr. Kathleen M. Kokolus, who holds a Ph.D. in Tumorolgy and works at the Roswell...
by cognosadminteam | Nov 2, 2021 | News
2 NOVEMBER, 2021 Co-Founder and CIO Josh Shachar Discusses the Evolution of the Cognos Vision In a recent presentation to the Cognos Shareholders, Josh Shachar, the Co-Founder and Chief Innovation Officer for Cognos Therapeutics presented a compelling vision for the...
by cognosadminteam | Nov 1, 2021 | News
Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including...
Recent Comments